Why Pfizer Is Still a Top Stock for 2021
Pharmaceutical giant Pfizer (NYSE: PFE) has been on a lot of investors' minds over the past 12 months. The company's breakthrough COVID-19 vaccine brought it to the forefront of national attention, and the stock performed nicely in 2020. I believe it can be successful in 2021 as well.
When the COVID-19 pandemic rocked the world, Pfizer stepped up and delivered. Within less than a year, Pfizer and BioNTech had entered into a joint partnership and developed the first vaccine to be approved under a U.S. Food and Drug Administration Emergency Use Authorization (EUA), on Dec. 11, 2020.
Since then, the world has placed several billion orders for the Pfizer/BioNTech COVID-19 vaccine, with the European Union currently in negotiations with the two companies for a third COVID-19 vaccine contract for almost 1.8 billion doses. This mega-contract would see the delivery of the vaccine to the European Union from 2021 until 2023.
Source Fool.com
